<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986996</url>
  </required_header>
  <id_info>
    <org_study_id>AntimicrobialUC</org_study_id>
    <nct_id>NCT03986996</nct_id>
  </id_info>
  <brief_title>Antimicrobial Therapy for Ulcerative Colitis (UC)</brief_title>
  <acronym>UC</acronym>
  <official_title>Antimicrobial Therapy for Ulcerative Colitis : Evaluation of Two Antibiotic Combinations for Refractory Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Aim of this study is to find a better treatment strategic for UC based on the recent
      knowledge regarding the microbiota in UC and the good and bad effects of antibiotics in
      promoting gut health and reduce infection. This study is design to determine whether therapy
      with two antibiotics - amoxicillin and doxycillin will be better than the current antibiotic
      treatment including metronidazole and or vancomycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies suggest that UC is associated with alterations of the microbiota. Further
      support for targeting the microbiota includes several studies demonstrating that antibiotics
      might be helpful for severe refractory colitis.

      Recently, a triple antibiotic therapy with amoxicillin, metronidazole and tetracycline
      developed for UC. However, a recent study on the effect of 11 different oral antibiotics on
      gut bacteria found that seven of them including metronidazole might cause leakiness of the
      gut.

      Based on these recent studies, it would appear that tetracycline and amoxicillin are more
      likely to cause the beneficial effect, while metronidazole might actually be detrimental.
      Thus by removing metronidazole the investigators might actually have a better effect both for
      efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 groups with 1:1 randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>The investigator will be blinded to the study group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - Clinical Response in group 1 and 2</measure>
    <time_frame>Week 3</time_frame>
    <description>Response defined as a 3 point drop in SCCAI / 20 point drop in PUCAI or drop in less than 3/20 point but entering clinical remission, defined as a SCCAI score&lt;5 / PUCAI score&lt;10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - Clinical Response in group 1 and 2</measure>
    <time_frame>Week 6</time_frame>
    <description>Mean SCCAI / PUCAI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFFICACY - Remission</measure>
    <time_frame>Week 6</time_frame>
    <description>SCCAI score&lt;5 / PUCAI score&lt;10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EFFICACY - PGA</measure>
    <time_frame>Week 6</time_frame>
    <description>Physicians Global Assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Group 1 -</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>triple therapy with amoxicillin, metronidazole and tetracycline twice daily, for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 -</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double therapy with Amoxycillin and Doxycyclin twice daily, for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin, metronidazole and tetracycline</intervention_name>
    <description>antibiotics</description>
    <arm_group_label>Group 1 -</arm_group_label>
    <other_name>Amoxy, Flagyl, Tetracycline hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin and tetracycline</intervention_name>
    <description>antibiotics</description>
    <arm_group_label>Group 2 -</arm_group_label>
    <other_name>Amoxy, Tetracycline hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Established diagnosis of UC, disease confined to the large intestine, involving the
             rectosigmoid for at least 3 months.

          2. Weight &gt;30 kg

          3. Mild to Moderate active disease, SCCAI of ≥5 and ≤ 10, 10 ≤ PUCAI ≤4.

          4. Refractory to mesalamine 6 weeks, or steroids &gt; 14 days, or immunomodulator 12 weeks
             or biologics at least 12 weeks therapy.

        Exclusion Criteria:

          1. Start of a new biologic in the previous 12 weeks.

          2. Proctitis

          3. Evidence for Clostridium difficile infection.

          4. Any proven current infection such as CMV, positive stool culture or parasite.

          5. Current Extra intestinal manifestation of UC such as active arthritis or PSC.

          6. Immune deficiency (other than drug induced).

          7. Current use of a calcineurin inhibitor

          8. Pregnancy.

          9. Suspected toxic megacolon, guarding on palpation, or signs of peritoneal inflammation

         10. Patients with other IBD unrelated disease such as autoimmune disorders, renal failure,
             fever or current infection (UTI, strep throat, pneumonia, etc), prior or current
             neoplasia

         11. Fever &gt;38

         12. Participation in another clinical interventional trial

         13. An active malignant disease or a prior malignancy during the previous 5 years
             (excluding skin BCC).

         14. Anticipation for antibiotic use within the study period (such as for elective surgery
             or dental treatment).

         15. Acute severe UC in the past 3 months.

         16. Presence of a pouch or pouchitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dror Weiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michal Yaakov, Ph.D</last_name>
    <phone>972-3-5028878</phone>
    <email>MICHALY@wmc.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>The E.Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 Nov 1;491(7422):119-24. doi: 10.1038/nature11582.</citation>
    <PMID>23128233</PMID>
  </reference>
  <reference>
    <citation>Manichanh C, Borruel N, Casellas F, Guarner F. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012 Oct;9(10):599-608. doi: 10.1038/nrgastro.2012.152. Epub 2012 Aug 21. Review.</citation>
    <PMID>22907164</PMID>
  </reference>
  <reference>
    <citation>Noor SO, Ridgway K, Scovell L, Kemsley EK, Lund EK, Jamieson C, Johnson IT, Narbad A. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol. 2010 Nov 12;10:134. doi: 10.1186/1471-230X-10-134.</citation>
    <PMID>21073731</PMID>
  </reference>
  <reference>
    <citation>Davenport M, Poles J, Leung JM, Wolff MJ, Abidi WM, Ullman T, Mayer L, Cho I, Loke P. Metabolic alterations to the mucosal microbiota in inflammatory bowel disease. Inflamm Bowel Dis. 2014 Apr;20(4):723-31. doi: 10.1097/MIB.0000000000000011.</citation>
    <PMID>24583479</PMID>
  </reference>
  <reference>
    <citation>David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014 Jan 23;505(7484):559-63. doi: 10.1038/nature12820. Epub 2013 Dec 11.</citation>
    <PMID>24336217</PMID>
  </reference>
  <reference>
    <citation>James SL, Christophersen CT, Bird AR, Conlon MA, Rosella O, Gibson PR, Muir JG. Abnormal fibre usage in UC in remission. Gut. 2015 Apr;64(4):562-70. doi: 10.1136/gutjnl-2014-307198. Epub 2014 Jul 18.</citation>
    <PMID>25037189</PMID>
  </reference>
  <reference>
    <citation>Khalil NA, Walton GE, Gibson GR, Tuohy KM, Andrews SC. In vitro batch cultures of gut microbiota from healthy and ulcerative colitis (UC) subjects suggest that sulphate-reducing bacteria levels are raised in UC and by a protein-rich diet. Int J Food Sci Nutr. 2014 Feb;65(1):79-88. doi: 10.3109/09637486.2013.825700. Epub 2013 Aug 13.</citation>
    <PMID>23941288</PMID>
  </reference>
  <reference>
    <citation>De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F, Rutgeerts P, Verbeke K. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. Inflamm Bowel Dis. 2012 Dec;18(12):2371-80. doi: 10.1002/ibd.22949. Epub 2012 Mar 20.</citation>
    <PMID>22434643</PMID>
  </reference>
  <reference>
    <citation>Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004 Oct;53(10):1479-84.</citation>
    <PMID>15361498</PMID>
  </reference>
  <reference>
    <citation>Pitcher MC, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut. 2000 Jan;46(1):64-72.</citation>
    <PMID>10601057</PMID>
  </reference>
  <reference>
    <citation>Ohkusa T, Nomura T, Terai T, Miwa H, Kobayashi O, Hojo M, Takei Y, Ogihara T, Hirai S, Okayasu I, Sato N. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol. 2005 Nov;40(11):1334-42.</citation>
    <PMID>16334443</PMID>
  </reference>
  <reference>
    <citation>Ohkusa T, Kato K, Terao S, Chiba T, Mabe K, Murakami K, Mizokami Y, Sugiyama T, Yanaka A, Takeuchi Y, Yamato S, Yokoyama T, Okayasu I, Watanabe S, Tajiri H, Sato N; Japan UC Antibiotic Therapy Study Group. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010 Aug;105(8):1820-9. doi: 10.1038/ajg.2010.84. Epub 2010 Mar 9.</citation>
    <PMID>20216533</PMID>
  </reference>
  <reference>
    <citation>Turner D, Levine A, Kolho KL, Shaoul R, Ledder O. Combination of oral antibiotics may be effective in severe pediatric ulcerative colitis: a preliminary report. J Crohns Colitis. 2014 Nov;8(11):1464-70. doi: 10.1016/j.crohns.2014.05.010. Epub 2014 Jun 20.</citation>
    <PMID>24958064</PMID>
  </reference>
  <reference>
    <citation>Terao S, Yamashiro K, Tamura I, Hirano T, Ohkusa T, Kato K. Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis. Digestion. 2011;83(3):198-203. doi: 10.1159/000321811. Epub 2011 Jan 21.</citation>
    <PMID>21266816</PMID>
  </reference>
  <reference>
    <citation>Kato K, Ohkusa T, Terao S, Chiba T, Murakami K, Yanaka A, Uehara T, Ishii Y, Soma M, Tajiri H. Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2014 May;39(9):949-56. doi: 10.1111/apt.12688. Epub 2014 Mar 13.</citation>
    <PMID>24628398</PMID>
  </reference>
  <reference>
    <citation>Knoop KA, McDonald KG, Kulkarni DH, Newberry RD. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut. 2016 Jul;65(7):1100-9. doi: 10.1136/gutjnl-2014-309059. Epub 2015 Jun 4.</citation>
    <PMID>26045138</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wolfson Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Arie Levine</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

